8-K: vTv Therapeutics Stockholders Re-Elect Board, Ratify Auditors at 2025 Annual Meeting

vTv Therapeutics Inc. announced the successful election of its seven director nominees and the ratification of Ernst & Young LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Summary

• vTv Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025.
• Stockholders elected seven director nominees to the Company's Board of Directors, each to serve until the 2026 annual meeting.
• The elected directors are Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard S. Nelson, Anne Phillips, Paul Sekhri, and Daniel K. Spiegelman.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by stockholders.

Sentiment

Score: 7

Explanation: The sentiment is positive as all proposed matters, including the election of directors and ratification of auditors, passed with strong shareholder support, indicating stability and adherence to corporate governance norms.

Positives

• All seven director nominees were successfully elected to the Board, indicating strong shareholder support for the current leadership.
• The ratification of Ernst & Young LLP as the independent auditor passed overwhelmingly, demonstrating confidence in the company's financial oversight.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding future financial performance or strategic initiatives.

Management Comments

• Michael Tung, Executive Vice President and Chief Financial Officer, signed the report on behalf of vTv Therapeutics Inc.

Industry Context

This filing is a standard corporate governance update for a publicly traded biotechnology company, reporting the outcomes of its annual stockholder meeting. It does not provide specific insights into broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the election of directors who will oversee company strategy and the ratification of auditors responsible for financial integrity.
• Management: The re-elected board provides continuity for the executive team.

Next Steps

• The elected directors will serve for a term to expire at the Company's 2026 annual meeting of stockholders or until their successors are duly elected and qualified.
• Ernst & Young LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

vTv Therapeutics, VTVT, Annual Meeting, Stockholders, Board of Directors, Director Election, Auditor Ratification, Ernst & Young LLP, Corporate Governance, SEC Filing, 8-K